Impact of Automated Insulin Delivery on Pregnancy Outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to understand the effects of automated insulin delivery (AID) systems on pregnant individuals with type 1 diabetes. Researchers will compare maternal and neonatal outcomes, glycemic control, and behavioral and emotional health between users of commercial and open-source AID systems. Participants will share their AID system data remotely and complete online surveys, while also allowing access to their medical records for comprehensive analysis.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Pregnant
* Diagnosis of type 1 diabetes (T1D) prior to pregnancy
* Active use of automated insulin delivery (AID) system

Exclusion criteria:

* Diagnosis of other forms of diabetes (gestational diabetes, type 2 diabetes, monogenic diabetes)

Where it's running

• University of California, San Francisco
  San Francisco, California, United States Recruiting

Study contacts

• Principal investigator: Nasim Sobhani, MD — University of California, San Francisco
• Study coordinator: Primary Investigator
• Email: cosclipstudy@ucsf.edu
• Phone: (415) 307-9319

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NOURISH: a community partnership to improve nutrition and glycemic control in pregnant women with pregestational diabetes

  Aiming to test a healthcare-community program that delivers healthy food weekly and provides nutrition education to pregnant women with type 1 or type 2 diabetes who have food insecurity, to improve blood sugar and pregnancy outcomes.

  Recruiting Ohio State University · Columbus, Ohio · NCT07560813

• Permissive versus strict blood sugar control during labor for pregnant people with type 1 diabetes

  This trial will test whether allowing slightly higher blood sugars (70–140 mg/dL) during labor is as safe for newborns as keeping tighter control (70–110 mg/dL) for pregnant people with type 1 diabetes using hybrid closed‑loop insulin systems.

  Recruiting Phase 4 Ohio State University · Columbus, Ohio · NCT07293715

• Observational study on the safety of relugolix therapy in pregnant women

  This study is trying to see if relugolix therapy is safe for pregnant women and their babies by looking at health outcomes during and after pregnancy.

  Recruiting Sumitomo Pharma Switzerland GmbH · Wilmington, North Carolina · NCT05739123

• Semaglutide on body composition in adults with type 1 diabetes and overweight/obesity

  This study tests whether weekly semaglutide changes body composition in adults with type 1 diabetes who are overweight or obese, compared with a placebo over 24 weeks.

  Recruiting Phase 2/3 McGill University Health Centre/Research Institute of the McGill University Health Centre · Montreal, Quebec · NCT07891156

• Next Generation Extended Wear Sensors in Type 1 and Type 2 Diabetes

  This study tests a new extended wear sensor and algorithm in people with type 1 or type 2 diabetes to see how well it works across adults and children.

  Recruiting at 11 sites Medtronic MiniMed, Inc. · Chula Vista, California and 17 other locations · NCT07864168

• CGM-guided carb awareness education for adults with Type 1 diabetes

  This study tests whether teaching mealtime insulin dosing using CGM data helps adults with Type 1 diabetes who don’t usually count carbs.

  Recruiting University of California, Los Angeles · Los Angeles, California · NCT07807280

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.